Halozyme Therapeutics, Inc. (HALO) 2019年年度报告「NASDAQ」.pdf

1、Annual Report 2019As I reflect back,I am very grateful for the tremendous energy and focus of our Halozyme team.Our key goals for the year were to deliver strong revenue growth and clinical progress in our ENHANZE business and conclude our HALO-301 PEGPH20 clinical trial,with plans to submit for reg

2、ulatory review assuming positive data.While the negative results of HALO-301 were disappointing,the closing of the oncology program opens a new,bright chapter for Halozyme,with ENHANZE as our foundation.In this years letter I want to tell the story of the planning and execution by the Halozyme team

3、and the Board of Directors that resulted in us being ready to take decisive action no matter the outcome of HALO-301.The key goals aligned with our two-pillar strategy,which we established in 2014 based on the promise of rHuPH20,our proprietary enzyme.rHuPH20 provided us with multiple avenues for va

4、lue creation at that time,and we chose to focus our efforts on our investigational new drug PEGPH20 and the ENHANZE drug delivery technology.We believed these two assets had the highest potential to meaningfully impact patients lives and to create long-term value for our shareholders,while also movi

5、ng us toward our long-term vision of building a leading biotechnology company.Pursuing a new drug for pancreas cancer is not for the faint of heart as the odds of success are low,but we knew our scientific rationale for doing so was strong.Informed by the promising Phase 2 data for PEGPH20,we initia

6、ted the definitive test for the drug with the Phase 3 HALO-301 study in 2016.At the same time,the ENHANZE drug delivery technology was gaining momen-tum with multiple new collaboration agreements and more products in clinical testing.The highly leverageable ENHANZE business model,with its increasing